We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $9.23 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's daily gain of 0.86%. Meanwhile, the Dow experienced a rise of 0.98%, and the technology-dominated Nasdaq saw an increase of 0.96%.
The stock of infectious disease drug developer has fallen by 0.21% in the past month, leading the Medical sector's loss of 2.34% and the S&P 500's loss of 1.96%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. The company's upcoming EPS is projected at $0.19, signifying a 18.75% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.78 per share and revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 12.09. This indicates a discount in contrast to its industry's Forward P/E of 20.3.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 167, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA - Free Report) closed at $9.23 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's daily gain of 0.86%. Meanwhile, the Dow experienced a rise of 0.98%, and the technology-dominated Nasdaq saw an increase of 0.96%.
The stock of infectious disease drug developer has fallen by 0.21% in the past month, leading the Medical sector's loss of 2.34% and the S&P 500's loss of 1.96%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. The company's upcoming EPS is projected at $0.19, signifying a 18.75% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.78 per share and revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 12.09. This indicates a discount in contrast to its industry's Forward P/E of 20.3.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 167, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.